Broadfin Capital’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Broadfin Capital’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-330,188	Closed	-$8.54M	–	78
2014 Q2	$8.54M	Sell	330,188 -50,000	-13%	-$1.11M	0.83%	39
2014 Q1	$8.88M	Buy	380,188 +58,800	+18%	+$1.29M	0.86%	38
2013 Q4	$8.16M	Buy	321,388 +253,088	+371%	+$5.72M	1.08%	32
2013 Q3	$1.39M	Buy	+68,300	New	+$1.52M	0.25%	55

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Broadfin Capital's SGNT Position: Q3 2014 in Review

Broadfin Capital sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2014, closing a stake of 330,188 shares — an estimated $8.54M sold.

Broadfin Capital first reported a position in SGNT in Q3 2013 and held it in 4 quarters. The position peaked at $8.88M in Q1 2014. 114 funds tracked by Wall St. Rank hold SGNT as of Q3 2014.

Broadfin Capital reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2014 after selling out during the quarter.
Broadfin Capital sold 330,188 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2014, an estimated $8.54M.
Broadfin Capital first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 4 quarters.
Broadfin Capital's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $8.88M in Q1 2014.
114 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2014.

Based on Broadfin Capital's 13F filing for Q3 2014, filed 14 Nov 2014.